![](https://www.diabetesnews.com/wp-content/uploads/2017/09/iStock-173753943-small-150x150.jpg)
New research led by the American insurance company Anthem Inc. looked at how the SGLT-2 inhibitor drug class, which includes drugs like Invokana and Jardiance, compares to the drugs in the DPP-4 inhibitor class (such as Januvia and Tradjenta). The study found a significant reduction in heart failure hospitalizations among older patients at risk of recurrent heart failure. Read more